Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
Comprehensive analysis of EGFR 19ins in lung cancer patients revealed genomic characteristics and clinical response, helping better inform clinical action and might facilitate the development of more precise therapeutic options for patients with these uncommon driver mutations.
Authors
- Yang Shao (ORCID: https://orcid.org/0000-0003-4585-1792)
- Yedan Chen (ORCID: https://orcid.org/0000-0002-7942-5540)
- Feng Lv (ORCID: https://orcid.org/0000-0003-0891-466X)
- Jiaohui Pang (ORCID: https://orcid.org/0009-0003-0689-560X)
- Yang Song (ORCID: https://orcid.org/0000-0002-4094-1388)
- Yang Li (ORCID: https://orcid.org/0000-0003-4399-1505)
- Long Huang
- Tao Wang (ORCID: https://orcid.org/0000-0002-7370-7299)
- Jie Min (ORCID: https://orcid.org/0000-0002-7629-5541)
- Yan Shi (ORCID: https://orcid.org/0000-0003-1671-860X)
- Xiaoying Wu (ORCID: https://orcid.org/0000-0002-7913-118X)
- Yunfeng Ni
Institutions
- Nanchang University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Genesee Community College (US)
- Air Force Medical University (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s12916-025-04075-1
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52